As of May 30, 2026, Foghorn Therapeutics's top three insider holders are Adrian Gottschalk (Chief Executive Officer, 511.70K shares), Adrian Gottschalk (Chief Executive Officer, 511.70K shares), Carl Decicco (Chief Scientific Officer, 362.71K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Simba Gill | - | 34,061 | 0 | 14 Sep, 2022 |
| Allan Reine | Chief Financial Officer | 53,784 | 0 | 11 Aug, 2021 |
| Adrian Gottschalk | Chief Executive Officer | 0 | 511,704 | 28 Apr, 2025 |
| Cigall Kadoch | - | 295,000 | 0 | 15 Dec, 2021 |
| Carl Decicco | Chief Scientific Officer | 362,707 | 0 | 13 Dec, 2021 |
| Steven F. Bellon | Chief Scientific Officer | 101,957 | 0 | 11 Sep, 2024 |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer | 75,992 | 0 | 12 Mar, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Apr, 2026 | Adrian Gottschalk | Common Stock | D | 47,497 | $0.00 | 0 | I | G |
| 09 Apr, 2026 | Adrian Gottschalk | Common Stock | D | 47,497 | $0.00 | 0 | I | G |
| 09 Apr, 2026 | Adrian Gottschalk | Common Stock | A | 47,497 | $0.00 | 211,704 | I | G |
| 09 Apr, 2026 | Adrian Gottschalk | Common Stock | A | 47,497 | $0.00 | 211,704 | I | G |
| 10 Apr, 2026 | Adrian Gottschalk | Common Stock | D | 59,208 | $0.00 | 240,792 | I | G |
| 10 Apr, 2026 | Adrian Gottschalk | Common Stock | D | 59,208 | $0.00 | 240,792 | I | G |
| 10 Apr, 2026 | Adrian Gottschalk | Common Stock | A | 59,208 | $0.00 | 270,912 | I | G |
| 10 Apr, 2026 | Adrian Gottschalk | Common Stock | A | 59,208 | $0.00 | 270,912 | I | G |
| 23 Feb, 2026 | Ryan D Maynard | Stock Option (right to buy) | A | 400,000 | $5.75 | 400,000 | D | A |
| 05 Feb, 2026 | Adrian Gottschalk | Stock option (right to buy) | A | 1,075,000 | $5.23 | 1,075,000 | D | A |
| 05 Feb, 2026 | Adrian Gottschalk | Stock option (right to buy) | A | 1,075,000 | $5.23 | 1,075,000 | D | A |
| 05 Feb, 2026 | Adrian Gottschalk | Stock option (right to buy) | A | 1,075,000 | $5.23 | 1,075,000 | D | A |
| 30 Jan, 2026 | Anna Rivkin | Stock option (right to buy) | A | 165,000 | $5.71 | 165,000 | D | A |
| 30 Jan, 2026 | Michael Lacascia | Stock option (right to buy) | A | 295,000 | $5.71 | 295,000 | D | A |
| 30 Jan, 2026 | Anna Rivkin | Stock option (right to buy) | A | 165,000 | $5.71 | 165,000 | D | A |
| 30 Jan, 2026 | Alfonso Quintas Cardama | Stock option (right to buy) | A | 300,000 | $5.71 | 300,000 | D | A |
| 30 Jan, 2026 | Carlos Costa | Stock option (right to buy) | A | 230,000 | $5.71 | 230,000 | D | A |
| 30 Jan, 2026 | Michael Lacascia | Stock option (right to buy) | A | 295,000 | $5.71 | 295,000 | D | A |
| 30 Jan, 2026 | Steven F. Bellon | Stock Option (right to buy) | A | 300,000 | $5.71 | 300,000 | D | A |
| 30 Jan, 2026 | Anna Rivkin | Stock option (right to buy) | A | 165,000 | $5.71 | 165,000 | D | A |